Successful Cardiac Transplantation in a Patient with Elevated Pulmonary Vascular Resistance: A Relative Contraindication to Transplantation


  • Cullen D. Morris
  • Ron D. Smith
  • Biswajit Kar
  • Ali Ghodsizad
  • Stephane Reverdin
  • O. H. Frazier
  • Igor D. Gregoric



Elevated pulmonary vascular resistance in a transplantation candidate should be viewed as potentially reversible, and there are several options for therapy. We describe a young patient with congenital restrictive cardiomyopathy and a markedly elevated pulmonary artery pressure. The patient underwent successful orthotopic heart transplantation after pharmacologic lowering of the pulmonary artery pressure with a new drug combination of milrinone and nesiritide. The length of therapy can be extended to 3 days to allow for determining the pulmonary vascular responsiveness.


Addonizio LJ, Gersony WM, Robbins RC, et al. 1987. Elevated pulmonary vascular resistance and cardiac transplantation. Circulation 76:V52-5.nBourge RC, Kirklin JK, Naftel DC, White C, Mason DA, Epstein AE. 1991. Analysis and predictors of pulmonary vascular resistance after cardiac transplantation. J Thorac Cardiovasc Surg 101:432-44, discussion 444-5.nColucci WS, Elkayam U, Horton DP, et al. 2000. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 343:246-53.nDelgado JF, Gomez-Sanchez MA, Saenz de la Calzada C, et al. 2001. Impact of mild pulmonary hypertension on mortality and pulmonary artery pressure profile after heart transplantation. J Heart Lung Transplant 20:942-8.nGriepp RB, Stinson EB, Dong E Jr, Clark DA, Shumway NE. 1971. Determinants of operative risk in human heart transplantation. Am J Surg 122:192-7.nKirklin JK, Young JB, McGiffin DC. 2002. Recipient evaluation and selection. In: Kirklin JK, Young JB, McGiffin DC, eds. Heart transplantation. New York, NY: Churchill Livingstone. p 198-231.nPamboukian SV, Carere RG, Webb JG, et al. 1999. The use of milrinone in pre-transplant assessment of patients with congestive heart failure and pulmonary hypertension. J Heart Lung Transplant 18:367-71.nPerez-Villa F, Cuppoletti A, Rossel V, Vallejos I, Roig E. 2006. Initial experience with bosentan therapy in patients considered ineligible for heart transplantation because of severe pulmonary hypertension. Clin Transplant 20:239-44.nRadovancevic B, Vrtovec B, Thomas CD, et al. 2005. Nitric oxide versus prostaglandin E1 for reduction of pulmonary hypertension in heart transplant candidates. J Heart Lung Transplant 24:690-5.n



How to Cite

Morris, C. D., Smith, R. D., Kar, B., Ghodsizad, A., Reverdin, S., Frazier, O. H., & Gregoric, I. D. (2009). Successful Cardiac Transplantation in a Patient with Elevated Pulmonary Vascular Resistance: A Relative Contraindication to Transplantation. The Heart Surgery Forum, 12(1), E59-E60.




Most read articles by the same author(s)

1 2 3 > >>